A method for the treatment or prevention of an undesirable immune response comprising the simultaneous administration of an immunosuppressant such as cyclosporine and a PPAR-gamma agonist such as pioglitazone or rosiglitazone. Undesirable immune responses include for example rheumatoid arthritis psoriasis systemic lupus erythematosus or transplant rejection.

Disclosed is a pharmaceutical composition comprising both rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof which is of use in the treatment or prophylaxis of Alzheimer's disease or other dementias and mild cognitive impairment. Also disclosed is an oral dosage forms comprising rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof.

An oral dosage form comprising an erodable core which core comprises Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent the core having a coating with one or more openings characterised in that the coating is erodable under predetermined pH conditions; a process for preparing such a dosage form and the use of such a dosage form in medicine.

An oral dosage form such as a bilayer tablet comprising a first layer of a first composition and a second layer of a second composition each composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione or a pharmaceutically acceptable salt or solvate thereof (‘the drug’) and a pharmaceutically acceptable carrier therefor wherein the first and second compositions are arranged to release drug at differing release rates on administration; a process for preparing s...

An oral dosage form comprising pellets of a first composition and pellets of a second composition each composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier therefor wherein the first and second compositions are arranged to release drug at differing release rates on administration preferably such that the rate of release of the drug from the dosage form is ...